Research

With our strong foundation in research, teaching and innovative clinical care, OSF HealthCare Cardiovascular Institute continues to be a leader in the field of cardiovascular medicine. We remain focused on our goals of providing a best-class patient experience while demonstrating superior outcomes.

Research

For over 30 years, the research department at OSF HealthCare Cardiovascular Institute has participated in research trials at our Peoria and Rockford offices. The research trials study cardiovascular medications and/or devices in general cardiology, interventional cardiology, electrophysiology, heart failure, vascular care and cardiothoracic care.

Many of our research trials are sponsored by international drug and device companies, like Pfizer or Boston Scientific, while other trials are initiated by OSF HealthCare Cardiovascular Institute providers.

All of our studies are approved by the Peoria Institutional Review Board (IRB) at the University of Illinois College of Medicine at Peoria or the Institutional Review Board of Record at OSF HealthCare Saint Anthony Medical Center in Rockford, depending on which location the study is taking place. The IRB’s are ethical review boards who protect human rights for those participating in research trials.

OSF HealthCare Cardiovascular Institute is proud to contribute to medical science through our trials and be a part of many state-of-the-art treatments being approved by the Food and Drug Administration (FDA). Through our research, we are able to deliver the most appropriate and advanced treatment options to our patients.

Medication Trials

  • PIONEER HF
  • PIONEER HF – a heart failure study, evaluating the safety and effectiveness of Entresto versus Enalapril, which are both FDA approved drugs. Entresto is a newer heart failure medication and has provided favorable results for symptom relief. However, the drug hasn’t been studied in the inpatient setting with patients showing sudden, worsening signs of heart failure. The study will determine if Entresto is more effective than Enalapril in the inpatient setting.
  • DAPA HF
  • DAPA HF – a heart failure study, evaluating the effects of Dapagliflozin (the study drug) versus a placebo (the sugar pill) on worsening heart failure in long-term heart failure and reduced ejection fraction* patients. Dapagliflozin is a medication used to treat Type 2 diabetes. During the research performed for Type 2 diabetes, the study found that the drug appeared to improve cardiovascular outcomes.
  • PRESERVED HF
  • PRESERVED HF – this study is similar to the DAPA HF study. However, it is evaluating the effects of Dapagliflozin versus the placebo on patients with heart failure and preserved ejection fraction.*
  • CLEAR
  • CLEAR – this study is for statin-intolerant patients at risk for cardiovascular disease. Statins are a variety of medications to help lower cholesterol levels in the blood. However, about 10 to 15 percent of the population is statin intolerant. This study is comparing a new drug called Bempedoic Acid (the study drug) versus a placebo. The main purpose of the study is to see if Bempedoic Acid reduces the risk of major cardiovascular events, like heart attacks or strokes in patients with, or at high risk for, heart disease, who have had complications related to taking statins. NCT02993406
  • EMPEROR
  • EMPEROR – a heart failure study, evaluating the effects of Empaglifozin (the study drug) versus a placebo on how well it treats patients with long-term heart failure with preserved or reduced ejection fraction.* Empaglifozin is currently a drug on the market being used to treat Type 2 diabetes.

    NCT03057977 and NCT03057951

    *Ejection fraction is percentage measurement of blood leaving your heart each time it contracts. If a patient has reduced ejection fraction that means less than 40 percent of their blood is pumped out each time it contracts. This affects how much blood is being distributed to the rest of the body. If a patient has preserved ejection fraction, the percent of blood being pumped from the heart each time it contracts is in normal range.

Device Trials

  • TIGRIS
  • TIGRIS – a study to determine the safety and effectiveness of the TIGRIS vascular stent versus an already FDA-approved stent. This study is for patients with peripheral artery disease, who require stents around the knee or femur area of the body. Peripheral artery disease is a condition that reduces blood flow to the limbs, like the legs. Stents in the legs are typically long and can fracture when a person is bending their knee, walking or do other everyday activities. The TIGRIS stent is newly designed in hopes of seeing less fractures. The study is to help evaluate if this new design is better than the existing FDA-approved stent.
  • PRESERVE II
  • PRESERVE II – a study to evaluate the safety and effectiveness of the COOK Branch Graft for patients with iliac aneurysms. Iliac aneurysms are bulges in the iliac arteries located in the pelvis that branch off the aorta. Current approved grafts would normally be inserted into the aneurysm to prevent the aneurysm from expanding further. But the graft would cut off blood supply to the internal iliac artery that provides blood to the intestines, reproductive organs and organs in the pelvis. With the new Branch Graft, the internal iliac artery would not be sealed off, keeping blood flow to those organs.  NCT01208415
  • GORE VIABAHN STENT GRAFT
  • GORE VIABAHN STENT GRAFT – a study to evaluate the safety and effectiveness of the Gore Graft for the treatment of in-stent restenosis. This study is for patients who have previously received a stent in the superficial femoral artery (SFA) - an artery in the thigh - that has now become partially or entirely blocked by plaque in the arteries. The purpose of this study is to confirm the safety and performance of the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface when used to treat SFA in-stent restenosis. The FDA has approved the device for use in treatment of in-stent restenosis of the superficial femoral artery. NCT02542267